Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes
Open accessAbstract
Importance: Recent studies have suggested an association between nonarteritic anterior ischemic optic neuropathy (NAION) with semaglutide usage. However, the limitations of those analyses warrant further investigation, given the frequency of use of these medications in people with and without diabetes. Objective: To investigate the association between semaglutide use and the risk of NAION among patients with diabetes. Design, Setting, and Participants: This cohort study used data from the TriNetX database between October 1, 2019, and December 31, 2023, to identify patients with diabetes with no history of NAION who were prescribed semaglutide. The semaglutide cohort was compared with a control group of randomly selected patients with diabetes who were prescribed non–glucagonlike peptide 1 (non–GLP-1) receptor agonist (RA) antidiabetic medications. The data analysis for this study was performed on September 1, 2024. Exposures: Semaglutide history, identified using diagnostic codes. Main Outcomes and Measures: Cumulative incidence and (HR) hazard ratio of NAION. Results: A total of 3 344 205 patients with diabetes were included in this study. Regarding the diabetes cohort, a total of 174 584 patients with diabetes who received semaglutide (mean [SD] age, 58.3 [12.5] years; 90 427 female [51.8%]; 71 739 male [41.1%]) and 174 584 patients with diabetes who received non–GLP-1 RA medications (mean [SD] age, 58.2 [14.3] years; 90 475 female [51.82%]; 71 989 male [41.24%]) were recruited. Patients with diabetes taking semaglutide exhibited an absence of NAION risk at the 1-month (HR, 2.99; 95% CI, 0.31-28.75), 3-month (HR, 1.33; 95% CI, 0.30-5.93), 6-month (HR, 1.79; 95% CI, 0.60-5.35), and 1-year (HR, 1.94; 95% CI: 0.93-4.02) time points after the index date. However, those taking semaglutide were found to have an increased risk for NAION at the 2-year (HR, 2.39; 95% CI, 1.37-4.18), 3-year (HR, 2.44; 95% CI, 1.44-4.12), and 4-year (HR, 2.05; 95% CI, 1.26-3.34) time points from the index date. Increased risk for NAION was also noted in patients with diabetes and concomitant hypertension who were taking semaglutide (HR, 2.42; 95% CI, 1.19-4.92). An increased NAION risk was also observed among patients with diabetes who had a history of Ozempic (Novo Nordisk) use or stand-alone Ozempic (Novo Nordisk) prescription history. Conclusions and Relevance: Results of this cohort study suggest that semaglutide use was associated with an increased risk of NAION in patients with diabetes. However, the study’s retrospective design presents limitations, as it can only infer associations rather than establish causality; further studies are needed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies show conflicting associations between semaglutide or GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy (NAION).
“Studies show conflicting associations.2,3,4,5,6,7,8,9”
From New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes (2026) · cites this paper as [3]
Large observational analyses reported similar 2- to 3-fold risks of NAION with GLP-1 receptor agonists, whereas others observed attenuated or null associations.
“Large observational analyses reported similar 2- to 3-fold risks,2,3,4,5 whereas others observed attenuated or null associations.6,7,8,9”
From New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes (2026) · cites this paper as [3]
Cites
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318 · see citing works
Hadi, Y. B., Naqvi, S. F., Kupec, J. T., Sofka, S., & Sarwari, A. R. (2021) · Transplantation · doi:10.1097/tp.0000000000003670 · Cited by 138 · see citing works
Boye, K. S., Thieu, V. T., Lage, M. J., Miller, H., & Paczkowski, R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02106-4 · Cited by 99 · see citing works
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72 · see citing works
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Chong, K., Chang, J. K.-J., & Chuang, L. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12800 · Cited by 70 · see citing works
Chen, T., Song, D., Shan, G., Wang, K., Wang, Y., Ma, J., & Zhong, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076653 · Cited by 69 · see citing works
Self-citationTran, S., Retnakaran, R. R., Zinman, B., & Kramer, C. K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13137 · Cited by 53 · see citing works
Should Steroids be Offered to Patients With Nonarteritic Anterior Ischemic Optic Neuropathy?
Lee, A. G., & Biousse, V. (2010) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e3181e1f71f · Cited by 52 · see citing works
Hadi, Y. B., Lakhani, D. A., Naqvi, S. F., Fatima, N. U., & Sarwari, A. R. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106606 · Cited by 41 · see citing works
Chatziralli, I., Kazantzis, D., Chatzirallis, A., Machairoudia, G., Papageorgiou, E. G., THEODOSSIADIS, G. P., Ψαλτοπούλου, Θ., THEODOSSIADIS, P. G., & Sergentanis, T. Ν. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05522-4 · Cited by 36 · see citing works
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Mollan, S. P. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2514 · Cited by 26 · see citing works
Risk Factors for Non-arteritic Anterior Ischaemic Optic Neuropathy in a Korean Population
Kim, D. H., Shin, G. R., & Choi, Y. J. (2017) · Neuro-Ophthalmology · doi:10.1080/01658107.2016.1267771 · Cited by 26 · see citing works
Martín-Gutiérrez, M. P., Petzold, A., & Saihan, Z. (2023) · Eye · doi:10.1038/s41433-023-02716-4 · Cited by 22 · see citing works
Sharma, S. M., Kwan, S., Fallano, K. A., Wang, J., Miller, N. R., & Subramanian, P. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.11.029 · Cited by 18 · see citing works
Mokhtarpour, K., Yadegar, A., Mohammadi, F., Aghayan, S. N., Seyedi, S. A., Rabizadeh, S., Esteghamati, A., & Nakhjavani, M. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.488 · Cited by 17 · see citing works
Cataract Development Among Pediatric Patients With Uveitis
Hsu, A. Y., Kuo, H., Lin, C.-J., Hsia, N., Kuo, S., Wei, C., Lai, C., Chen, H., Wang, Y., Wei, J. C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.19366 · Cited by 17 · see citing works
Self-citationPractical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & SKOLNIK, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14 · see citing works
Shew, W., Wang, M. T. M., & Danesh-Meyer, H. V. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001625 · Cited by 14 · see citing works
Stroke Risk Following Nonarteritic Anterior Ischemic Optic Neuropathy
Chu, Y.-Y., Ho, C., Chen, Y., & Kuo, S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.44534 · Cited by 12 · see citing works
Systemic-Related Factors of Nonarteritic Anterior Ischemic Optic Neuropathy
Xiao, Y.-Y., Wei, W., Wang, Y. X., Lu, A.-D., Chen, S., Song, L., & Wu, S. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.241795 · Cited by 10 · see citing works
Self-citationShurraw, S., & Tonelli, M. A. (2013) · Kidney International · doi:10.1038/ki.2012.431 · Cited by 5 · see citing works
Lusk, J. B., Grory, B. M., & Fan, L. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4515 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tesfaye, H., Paik, J. M., Wexler, D. J., Carreno-Galeano, J. T., Yu, E. W.-Y., Freedman, A., Rizzo, J. F., & Patorno, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70200 · Cited by 18 · see citing works
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100245 · Cited by 21 · see citing works
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 16 · see citing works
Heberer, K., Bress, A. P., Cogill, S., Maldonado, A. I., Kim, S. H., Nallamshetty, S., Chen, Y. Q., Shih, M.-C., Lynch, J. A., & Lee, J. S. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.6262 · Cited by 18 · see citing works
Feldman-Billard, S. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101664 · Cited by 12 · see citing works
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y.-H. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 10 · see citing works
Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy
Abdelaal, A., Serhan, H. A. A., Alsaadi, M., Yaldo, L. M., Gaier, E. D., & Elhusseiny, A. M. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.02.013 · Cited by 9 · see citing works
Özbek, L., Güldan, M., Fidan, D. G., Abdel‐Rahman, S. M., & Kanbay, M. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.05.011 · Cited by 8 · see citing works
Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication
Gaćina, D. L., Vidović, T., Oreb, N. V., Matković, L., & Jandroković, S. (2025) · Reports — Medical Cases Images and Videos · doi:10.3390/reports8030149 · Cited by 8 · see citing works
Noh, Y., Yin, H., Ghezala, I. B., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2026) · Diabetes Care · doi:10.2337/dc25-2577 · Cited by 9 · see citing works
Conflicting Results—Need for More Transparent and Reproducible Research
Cai, C. X., Hribar, M. R., & Nishimura, A. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.0350 · Cited by 8 · see citing works
BBiomed, Z. L., Raveendran, D., Fourlanos, S., & Chong, E. W. T. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.12.022 · Cited by 9 · see citing works
Dhivagaran, T., Butt, F. R., Arunasalam, L., Bae, I., Mikhail, D., Tao, B. K.-L., Xie, J. S., Balas, M., Popovic, M. M., & Margolin, E. (2026) · Neurology · doi:10.1212/wnl.0000000000214864 · Cited by 7 · see citing works
DeParis, S. W., Oke, I., Gaier, E. D., Moss, H. E., MacIntosh, P. W., Gilbert, A. L., Dinkin, M., & Chen, J. J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.04.008 · Cited by 8 · see citing works
Nadeem, N., Issa, R. M. A., Shah, A., Wardeh, R., Rashid, F., Abdelgadir, E., & Bashier, A. M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.07.002 · Cited by 7 · see citing works
NAION risk with semaglutide: what we know so far
Hsu, A. Y., Wang, Y., Lin, C., Hsia, N.-Y., Shao, Y.-C., Chiang, C.-C., Chen, H., Tsai, Y., & Wei, J. C.-C. (2025) · Eye · doi:10.1038/s41433-025-03833-y · Cited by 6 · see citing works
Self-citationChrzanowski, J., Walicka, M., Burzyński, J., Zaraś, M., Michalak, A., & Fendler, W. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005064 · Cited by 6 · see citing works
Goldenberg, R., Aronson, R., & Trinacty, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70013 · Cited by 5 · see citing works
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 5 · see citing works
Chen, J.-W., Yu, F. T.-E., Chen, H.-A., Huang, T.-F., Chen, H.-S., & Wu, T.-E. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101740 · Cited by 4 · see citing works
Self-citationBloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70085 · Cited by 3 · see citing works
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3 · see citing works
Varghese, D., Abdelsalam, D., Ibrahim, S., Lee, A. G., & Bhatti, M. T. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.01.001 · Cited by 2 · see citing works
Bakheet, M., & Chaudhary, A. (2026) · Cureus · doi:10.7759/cureus.102472 · Cited by 2 · see citing works
Lee, Y. K., Chang, Y. Y., Jang, H. N., Ma, D. J., & Song, H. B. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119635 · Cited by 2 · see citing works
Robertson, C. M., Fung, D., Smith, K. H., Lai, K. E., Guniganti, R., Rizzo, J. F., & Lao, K. C. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.07.036 · Cited by 2 · see citing works
Liu, L. Q., Mohan, S., & Wu, L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf541 · Cited by 2 · see citing works
Yang, S., Ren, D., Li, C., Yang, Z., Hou, X., Zhao, C., Niu, L., & Li, Z. Y. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01298-6 · Cited by 1 · see citing works
Barnett, M. J., Ibe, F. O., & Lam, J. (2026) · Cureus · doi:10.7759/cureus.100953 · Cited by 1 · see citing works
Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists
Lixi, F., Troisi, M., Calabresi, V., Giagoni, A., Rossi, C., Timofte-Zorila, M.-M., Tarași, T.-C., Vitiello, L., Tomi, M.-I., Gheorghe, A. G., et al. (2026) · Vision · doi:10.3390/vision10020029 · Cited by 2 · see citing works
Lampsas, S., Agapitou, C., Oikonomou, E., Siasos, G., Theodossiadis, P., Tsivgoulis, G. K., Lambadiari, V., & Chatziralli, I. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07291-4 · Cited by 1 · see citing works
Atypical retrobulbar optic neuropathy after semaglutide escalation
Channabasappa, S., Gupta, R. D., Chandran, V., & Prasad, S. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag108 · Cited by 2 · see citing works
Kakkar, A. K., Payra, S., & Charaya, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70952 · Cited by 1 · see citing works
Andreão, F. F., Amaral, D. C., Magalhães, P. L. M., Cheidde, L., Louzada, R. N., Monteiro, M. L. R., & Santos, D. H. (2026) · AJO International · doi:10.1016/j.ajoint.2026.100275 · Cited by 1 · see citing works
Khani, E., Asham, H., Rezabakhsh, A., Babaei, S., & Entezari‐Maleki, T. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70248 · Cited by 1 · see citing works
Semaglutide-related ischaemic optic neuropathy
(2025) · Reactions Weekly · doi:10.1007/s40278-025-80247-1
Abbass, N. J., Allan, K. C., Talcott, K. E., & Singh, R. P. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.06.025
Hsu, A. Y., Lin, C., Shao, Y.-C., Tsai, Y., Wang, Y., & Wei, J. C.-C. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.053
Self-citation(2025) · Nursing · doi:10.1097/nsg.0000000000000235
Incorrect Conclusions From Misinterpreting Point Estimates and CIs
Etminan, M., Sodhi, M., & Mansournia, M. A. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2248
Incorrect Conclusions From Misinterpreting Point Estimates and CIs—Reply
Hsu, A. Y., Lin, C.-J., & Wei, J. C.-C. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2251
Self-citationHeberer, K. R., Bress, A. P., Cogill, S., Maldonado, A. I., Kim, S. H., Nallamshetty, S., Chen, Y. Q., Shih, M.-C., Lynch, J. A., & Lee, J. S. (2025) · medRxiv · doi:10.1101/2025.09.15.25335753
Lee, Y. K., Chang, Y. Y., Jang, H. N., Ma, D. J., & Song, H. B. (2025) · medRxiv · doi:10.1101/2025.09.25.25336128
Nitzan, I., Gaier, E. D., Cestari, D. M., Eshel, Y., & Kruger, J. M. (2025) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002416
Acute Ischemic Stroke in Non-Arteritic Anterior Ischemic Optic Neuropathy
Wenzel, V., Danyel, L. A., Meidinger, S., Siebert, E., Knoche, T., & Pietrock, C. (2025) · Diagnostics · doi:10.3390/diagnostics15243192
Self-Management Interventions for Chronic Liver Disease: A Scoping Review
Gonzalez, C., Prado-Nava, M., & Groessl, E. J. (2025) · American Journal of Health Behavior · doi:10.5993/ajhb.49.5.3
Jarrett, E., Muayad, J., Ryu, B. U., Lee, A. G., & Gupta, P. K. (2026) · Clinical ophthalmology · doi:10.2147/opth.s581826
Sharma, A., Wu, L., Bloom, S., Stanga, P. E., Cai, C. X., Singh, R. P., Verghese, S., Chandrakanth, P., Prabha, D., & Rezaei, K. A. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260114-01
Lange, M. G., Vickers, A., Hill, L. J., Mollan, S. P., Mitchell, J., Sinclair, A. J., & Lee, A. G. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002431
Maideen, N. M. P., Rashid, S. A., Balasubramanian, R., & Amirthalingam, P. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2659_25
Baumal, C. R., Choi, S. H., Balonov, K., & Diana, V. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260310-01
Danesh-Meyer, H. V., & Rizzo, J. F. (2026) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70096
Anti-obesity medications impacting the eye: An emerging concern - a narrative review
Khullar, S., Morya, A. K., Aggarwal, S., Singh, A., Sisodiya, P., & Morya, R. (2026) · World Journal of Methodology · doi:10.5662/wjm.118520
What an Ophthalmologist Should Know about the Side Effects of “Ozempic” and its Analogues
Николаевич, Т. В., Полунина, Е. Г., Trubilin, А. V., Кечин, Е. В., Анджелова, Д. В., Konovalov, M. E., Privezentseva, T. A., & Fedoseyev, Y. B. (2026) · Ophthalmology in Russia · doi:10.18008/1816-5095-2026-2-234-241
Data and Temporal Risk Concerns of Semaglutide and NAION
Yu, C.-H. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2026.3445
THE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON OCULAR DISEASES: A NARRATIVE REVIEW
Gąsowski, D., Dapkiewicz, E., Haba, S., Bołoz, M., Smolińska, A., Szewczyk, J., Grzyb, I., Wątek, Z., Łysynkiewicz, K., & Krawczyk, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6144
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025
Sun, H., Xin, X., Yan, J., & Huang, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71358
Uddaraju, M., Penmatsa, S., Laveti, S. N., & Vaishali, K. V. (2024) · Journal of ophthalmology clinics and research. · doi:10.4103/jocr.jocr_10_26
Alabed, S. T., Thomas, A., Szirth, B. C., & Khouri, A. S. (2026) · Neuro-Ophthalmology · doi:10.1080/01658107.2026.2741570
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Ueda, P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70170
Yeo, G. E., & Kim, J. H. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e345
- Authors
- Hsu, A. Y., Kuo, H.-T., Wang, Y.-H., Lin, C.-J., Shao, Y.-C., Chiang, C.-C., Hsia, N.-Y., Lai, C.-T., Tseng, H., Wu, B.-Q., Chen, H.-S., Tsai, Y.-Y., Hsu, M.-Y., & Wei, J. C.-C.
- Affiliations
- China Medical University (TW)
- Chung Shan Medical University Hospital (TW)
- Asia University (TW)
- An-Shin Dialysis Center, Excelsior Renal Service Co Ltd, Taiwan Branch, Taichung, Taiwan
- ORCID
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2025-05-01
- Volume
- 143
- Issue
- 5
- Pages
- 400
- ISSN
- 2168-6165 (ISSN-L)
- OpenAlex
- W4408905880
- Cited by
- 62
- References
- 22
- Citations by year
- 2026: 34 · 2025: 27 · 2024: 1
- FWCI
- 41.60
- Type
- journal article
- Language
- en
- Open access
- Locations
- JAMA Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- semaglutide, nonarteritic anterior ischemic optic neuropathy, diabetes mellitus, GLP-1 receptor agonists, antidiabetic drugs, adverse drug reactions, drug safety, optic neuropathy, hazard ratio, cumulative incidence, drug exposure duration, age and sex differences
- MeSH terms
- Semaglutide, Aged, Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Risk Factors, Incidence, Databases, Factual, Optic Neuropathy, Ischemic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
